Yang Xiaotian

Company snapshot

Yang Xiaotian is a pharma organization headquartered in CN. Primary therapeutic focus areas include Bleeding Complication During Colon Polypectomy, Cancer of Colon, Erosive Esophagitis, Gastric Cancer, Primary Aldosteronism. NovaPharmaNews links 5 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (1), phase 3 (1), approved (1).

• 5 active pipeline program(s) linked via ClinicalTrials.gov.
• 5 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Yang Xiaotian. Not investment advice.

• What is Yang Xiaotian?

  Yang Xiaotian is a pharma organization headquartered in CN. Primary therapeutic focus areas include Bleeding Complication During Colon Polypectomy, Cancer of Colon, Erosive Esophagitis, Gastric Cancer, Primary Aldosteronism. NovaPharmaNews links 5 clinical program(s), 0 drug prof

• Is Yang Xiaotian publicly traded?

  Yang Xiaotian appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Yang Xiaotian develop or market?

  We link 2 drug profile(s) where Yang Xiaotian is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/yang-xiaotian#company-drugs.

• What are the latest developments for Yang Xiaotian?

  In the last 12 months our linked public records show 5 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Yang Xiaotian focus on?

  Yang Xiaotian focuses on Bleeding Complication During Colon Polypectomy, Cancer of Colon, Erosive Esophagitis based on our analysis of their pipeline programs and drug development activities.